Definium Therapeutics Inc. Common Shares vs Clear Secure Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.73 (market cap $4.59B), while Clear Secure Inc trades at $43.26 (market cap $4.44B). The key difference: Definium Therapeutics Inc. Common Shares and Clear Secure Inc are close in size by market cap, and Clear Secure Inc pays a 1.33% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Clear Secure Inc for 19 Days on average.
| DFTX | YOU | |
|---|---|---|
Market Cap | $4.59B | $4.44B |
Volume | 2,103,937 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $48.45 | $62.36 |
52-Week Low | $10.68 | $29.61 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $3.55B | $3.59B |
Dividend Yield | — | 1.33% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Clear Secure (YOU) trades at $43.26, up 1.59% today, with a bullish technical signal despite mixed moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $0.49 versus $0.40 expected, and revenue growth accelerated to 27% year-over-year. Profitability remains robust with a net margin of 14.78% and ROE of 90.29%, though valuation multiples like P/E of 29.11 appear elevated. Recent news highlights strategic partnerships, such as the integration with CrowdStrike's Falcon platform, and the launch of corporate memberships.
The outlook is positive given earnings momentum and expanding market opportunities, but risks include high valuation sensitivity and competitive pressures. Analysts are generally bullish with a consensus price target of $61.40, implying significant upside, though insider selling and overbought RSI levels warrant caution for near-term volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →